Safety and Efficacy of Pimecrolimus in Atopic Dermatitis: A 5-Year Randomized Trial

Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial.

BACKGROUND AND OBJECTIVES Atopic dermatitis (AD) primarily affects infants and young children. Although topical corticosteroids (TCSs) are often prescribed, noncorticosteroid treatments are needed because compliance with TCSs is poor due to concerns about their side effects. In this longest and largest intervention study ever conducted in infants with mild-to-moderate AD, pimecrolimus 1% cream ...

Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children.

OBJECTIVE Pimecrolimus cream (SDZ ASM 981), a nonsteroid inhibitor of inflammatory cytokines, is effective in atopic dermatitis (AD). We assessed whether early treatment of AD signs/symptoms with pimecrolimus could influence long-term outcome by preventing disease flares. METHODS Early intervention with pimecrolimus was compared with a conventional AD treatment strategy (ie, emollients and to...

Pimecrolimus in dermatology: atopic dermatitis and beyond.

Pimecrolimus is a calcineurin inhibitor developed for the topical therapy of inflammatory skin diseases, particularly atopic dermatitis (AD). Pimecrolimus selectively targets T cells and mast cells. Pimecrolimus inhibits T-cell proliferation, as well as production and release of interleukin-2 (IL-2), IL-4, interferon-gamma and tumour necrosis factor-alpha. Moreover, pimecrolimus inhibits mast c...

Pimecrolimus for the treatment of atopic dermatitis

Receive summaries of articles in each month’s issue of Pediatrics when you sign up at www.pediatrics.org. Safety and Efficacy of Pimecrolimus in Atopic Dermatitis: A 5-Year Randomized Trial